JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Strona główna・Stock List・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Closed

SectorHealthcare

21.79 -4.72

Buy Sell

Overview

Share price change

24h

Current

Min

21.43

Max

22.77

Key metrics
By Trading Economics
Income	-14M -50M
Sales	12M 128M
Profit margin	-39.506
Employees	1,784
EBITDA	-17M -48M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+54.22% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	642M 2.9B
Previous open	26.51
Previous close	21.79

News Sentiment

By Acuity

34%

66%

121 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

28.13 / 31.12 Support & Resistance

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 kwi 2026, 00:00 UTC

Earnings

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24 kwi 2026, 00:00 UTC

Earnings

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23 kwi 2026, 23:47 UTC

Market Talk

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 kwi 2026, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 kwi 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

23 kwi 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 kwi 2026, 23:13 UTC

Acquisitions, Mergers, Takeovers

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 kwi 2026, 22:33 UTC

Earnings

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 kwi 2026, 22:17 UTC

Earnings

PLS Executed Offtake Agreement With Ronbay

23 kwi 2026, 22:17 UTC

Earnings

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 kwi 2026, 22:16 UTC

Earnings

PLS Commences Commissioning of Midstream Demonstration Plant

23 kwi 2026, 22:15 UTC

Earnings

PLS Group Reaffirms FY26 Guidance for All Metrics

23 kwi 2026, 22:14 UTC

Earnings

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 kwi 2026, 22:14 UTC

Earnings

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 kwi 2026, 22:13 UTC

Earnings

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 kwi 2026, 22:12 UTC

Earnings

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 kwi 2026, 22:12 UTC

Earnings

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 kwi 2026, 22:11 UTC

Earnings

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 kwi 2026, 22:10 UTC

Earnings

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 kwi 2026, 22:09 UTC

Earnings

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 kwi 2026, 22:08 UTC

Earnings

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 kwi 2026, 22:04 UTC

Earnings

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 kwi 2026, 21:56 UTC

Market Talk

Earnings

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 kwi 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 kwi 2026, 21:27 UTC

Earnings

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 kwi 2026, 21:25 UTC

Earnings

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 kwi 2026, 21:24 UTC

Earnings

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 kwi 2026, 21:24 UTC

Earnings

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 kwi 2026, 21:21 UTC

Earnings

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 kwi 2026, 21:21 UTC

Earnings

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

54.22% upside

12 Months Forecast

Average 35.27 USD 54.22%

High 47 USD

Low 21.8 USD

Based on 4 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

121 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.